Cell ReportsCancer BiologyPeer-reviewed journal article
E2 displacement of CIP2A from TOPBP1 activates the DNA damage response during papillomavirus life cycles
Apurva Tadimari PrabhakariD, Claire D. JamesiD, A. NguyeniD, Phoebe V. Bridy, Xu WangiD, Ryan J. Zoldork, Jenny D Roe, Austin J. Witt, Srimanya S. Panidepu, Sarita GiriiD, Molly L. BristoliD, Krista Dalton, Andreas WielandiD, Ahmed DiabiD, Anthony C. FaberiD, Elliot J. AndrophyiD, Devraj BasuiD, Paul F. LambertiD, Megan E. SpurgeoniD, Iain M. MorganiD
Abstract
The papillomavirus life cycle is intricately linked to epithelial differentiation, and the virus manipulates the differentiation process to facilitate viral production. One such manipulation is activation of the DNA damage response (DDR) which promotes viral replication via homologous recombination. This report demonstrates that the papillomavirus transcription/replication/segregation factor E2 activates the DNA damage response (DDR). During differentiation, E2 displacement of CIP2A from TOPBP1 causes CIP2A to bind and inhibit PP2A resulting in DDR activation via ATM phosphorylation. The DDR promotes inhibitory interaction of DBC1 with the class III deacetylase SIRT1, which further boosts the DDR via increased acetylation and stability of viral and host proteins. E2 forms a complex with TOPBP1 and ATM, while preventing ATR activation by blocking TOPBP1-ATR interaction. This "ATM up ATR down" phenotype promotes viral replication via ATM promotion of homologous recombination, and cell proliferation via inhibition of ATR. We demonstrate this mechanism of DDR activation in multiple systems: keratinocytes expressing only E2, in foreskin keratinocytes immortalized by HPV16, in HPV16 positive keratinocytes derived from a cervical lesion, in pre-neoplastic lesions induced by mouse papillomavirus MmuPV1, in head and neck cancer cell lines that retain E2 expression, and in HPV16 positive oropharyngeal patient derived xenografts that retain E2 expression. ATM inhibition preferentially killed cells expressing E2, presenting a novel strategy for treating HPV early preneoplasia and a large subset of HPV+ oropharyngeal cancers retaining E2 expression and episomal genomes.
- organism: human
- organism: mouse
- assay: proteomics
- research focus: host-pathogen & immune response
- research focus: drug response / drug discovery
- approach: experimental assay
- Citations
- 3
- FWCI
- 13.84
- Field percentile
- top 2%
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- Topoisomerase IIα orchestrates secretion of IL-6 and IL-8 with human papillomavirus replication
Yanfei Liu, Zhe Han, … Shiyuan Hong·Virologica SinicaPeer-reviewed·Nov 20, 2025
- Differentiation-Dependent Proximity Proteomics Identifies Novel Host Factors Linked to HPV16 E2 Function
Claire D. James, Aya H. Youssef, … Iain M. Morgan·mBioPeer-reviewed·Jan 12, 2026
- CK2 phosphorylation of human papillomavirus 16 E2 on serine 23 promotes interaction with TopBP1 and is critical for E2 plasmid retention function
Apurva Tadimari Prabhakar, Claire D. James, … Iain M. Morgan·bioRxiv·Feb 17, 2021
- Human papillomavirus 16 E2 interaction with TopBP1 is required for E2 and viral genome stability during the viral life cycle.
A. Tadimari Prabhakar, C. D. James, … I. M. Morgan·bioRxiv·Jan 11, 2023
- Interaction with TopBP1 mediates human papillomavirus 16 E2 plasmid segregation/retention function and stability during the viral life cycle
Apurva Tadimari Prabhakar, Claire D. James, … Iain M. Morgan·bioRxiv·Jan 28, 2022
- Werner helicase control of human papillomavirus 16 E1-E2 DNA replication is regulated by SIRT1 deacetylation
I. M. Morgan, D. Das, … P. Pichierri·bioRxiv·Oct 23, 2018